Menopausal hormone therapy; bone health in menopause; cancer risk and menopausal hormone therapy; cardiovascular risk menopause; sexual function and dysfunction; sleep disturbances in menopause; urogenital symptom treatment; vasomotor symptoms; Humans; Female; Estrogen Replacement Therapy; Hormone Replacement Therapy; Congresses as Topic; Menopause; Practice Guidelines as Topic; Obstetrics and Gynecology
Abstract :
[en] The 19th World Congress on Menopause, hosted by the International Menopause Society in 2024, convened global experts to discuss the latest advances in menopause management. This review highlights key focus areas presented at the congress, offering insights into best practices for clinical application. Cardiovascular health remains a priority, with emphasis on recognizing sex-specific risk factors and exploring emerging therapies. Osteoporosis management underscores the role of menopausal hormone therapy (MHT) as foundational, complemented by anti-resorptive and bone-forming agents in high-risk populations and those not candidates for MHT. Addressing genitourinary symptoms and sexual health, vaginal estrogen therapy is confirmed as a safe and effective option with vaginal dehydroepiandrosterone (DHEA) and oral ospemifene as suitable alternatives, while testosterone therapy offers benefits for hypoactive sexual desire disorder in postmenopausal women. Sleep disturbances, depression and workplace challenges linked to menopause were explored, with tailored interventions such as MHT and cognitive behavioral therapy specifically for sleep recommended. Cancer risk management stressed the need for a multidisciplinary approach to risk reduction beginning with lifestyle modification, and with non-hormonal therapies prioritized for symptomatic treatment of menopausal symptoms in those with hormone-sensitive cancers. Lastly, perimenopause management highlighted comprehensive approaches integrating symptom relief and contraceptive needs.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Simon, James A; Department of Obstetrics and Gynecology, George Washington University and IntimMedicine Specialists, Washington, DC, USA
Davis, Susan R; Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Lindén Hirschberg, Angelica; Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Kiesel, Ludwig; Department of Obstetrics and Gynecology, University Hospital Münster, Münster, Germany
Pompei, Luciano de Melo; Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina do ABC, Santo André, Brazil
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique ; Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Simoncini, Tommaso; Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy
Hillard, Timothy; Department of Obstetrics and Gynaecology, University Hospitals Dorset, Poole, UK
Language :
English
Title :
State of the art in menopause: current best practice approaches from the IMS World Congress 2024, Melbourne.
Publication date :
April 2025
Journal title :
Climacteric: the Journal of the International Menopause Society
Panay N, Anderson RA, Bennie A, et al.Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024;27(6):510–520. doi: 10.1080/13697137.2024.2408922.
Davis SR, Lambrinoudaki I, Lumsden M, et al.Menopause. Nat Rev Dis Primers. 2015;1(1):15004. doi: 10.1038/nrdp.2015.4.
Ma Z, Chen J, Jin K, et al.Colchicine and coronary heart disease risks: a meta-analysis of randomized controlled clinical trials. Front Cardiovasc Med. 2022;9:947959. doi: 10.3389/fcvm.2022.947959.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. doi: 10.1056/NEJMoa2307563.
Greendale GA, Sowers M, Han W, et al.Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res. 2012;27(1):111–118. doi: 10.1002/jbmr.534.
Shi V, Morgan EF., Estrogen and estrogen receptors mediate the mechanobiology of bone disease and repair. Bone. 2024;188:117220. doi: 10.1016/j.bone.2024.117220.
Shieh A, Greendale GA, Cauley JA, et al.The association between fast increase in bone turnover during the menopause transition and subsequent fracture. J Clin Endocrinol Metab. 2020;105(4):e1440–e1448. doi: 10.1210/clinem/dgz281.
Anagnostis P, Lallas K, Pappa A, et al.The association of vasomotor symptoms with fracture risk and bone mineral density in postmenopausal women: a systematic review and meta-analysis of observational studies. Osteoporos Int. 2024;35(8):1329–1336. doi: 10.1007/s00198-024-07075-8.
Genazzani AR, Divakar H, Khadilkar SS, et al.Counseling in menopausal women: how to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int J Gynaecol Obstet. 2024;164(2):516–530. doi: 10.1002/ijgo.15278.
Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al.Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?Osteoporos Int. 2020;31(12):2271–2286. doi: 10.1007/s00198-020-05497-8.
Cauley JA, Robbins J, Chen Z, et al.Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738. doi: 10.1001/jama.290.13.1729.
Lorentzon M, Johansson H, Harvey NC, et al.Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women’s Health Initiative hormone therapy trials. Osteoporos Int. 2022;33(11):2297–2305. doi: 10.1007/s00198-022-06483-y.
Zhu L, Jiang X, Sun Y, et al.Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461–470. doi: 10.1097/GME.0000000000000519.
Kanis JA, Harvey NC, McCloskey E, et al.Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12. doi: 10.1007/s00198-019-05176-3.
Santoro N, Komi J., Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133–2142. doi: 10.1111/j.1743-6109.2009.01335.x.
Palacios S, Nappi RE, Bruyniks N, et al.The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291. doi: 10.1080/13697137.2018.1446930.
Moore KH, Ognenovska S, Chua X-Y, et al.Change in microbiota profile after vaginal estriol cream in postmenopausal women with stress incontinence. Front Microbiol. 2024;15:1302819. doi: 10.3389/fmicb.2024.1302819.
Hirschberg AL, Bitzer J, Cano A, et al.Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021;148:55–61. doi: 10.1016/j.maturitas.2021.04.005.
Constantine GD, Graham S, Lapane K, et al.Endometrial safety of low-dose vaginal Estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800–807. doi: 10.1097/GME.0000000000001315.
Danan ER, Sowerby C, Ullman KE, et al.Hormonal treatments and vaginal moisturizers for genitourinary syndrome of menopause. Ann Intern Med. 2024;177(10):1400–1414. doi: 10.7326/ANNALS-24-00610.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. 2019;394(10204):1159–1168.
Biglia N, Cozzarella M, Cacciari F, et al.Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003;45(1):29–38. doi: 10.1016/s0378-5122(03)00087-2.
Parish SJ, Simon JA, Davis SR, et al.International society for the study of women’s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021;18(5):849–867. doi: 10.1016/j.jsxm.2020.10.009.
Islam RM, Bell RJ, Green S, et al.Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi: 10.1016/S2213-8587(19)30189-5.
Chaput J-P, McHill AW, Cox RC, et al.The role of insufficient sleep and circadian misalignment in obesity. Nat Rev Endocrinol. 2023;19(2):82–97. doi: 10.1038/s41574-022-00747-7.
Chaput J-P, Dutil C, Featherstone R, et al.Sleep duration and health in adults: an overview of systematic reviews. Appl Physiol Nutr Metab. 2020;45(10 (Suppl. 2):S218–S231. doi: 10.1139/apnm-2020-0034.
Baril A, Beiser AS, Sanchez E, et al.Insomnia symptom severity and cognitive performance: moderating role of APOE genotype. Alzheimers Dement. 2022;18(3):408–421. doi: 10.1002/alz.12405.
Guthrie KA, Larson JC, Ensrud KE, et al.Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: a pooled analysis of individual participant data from four MsFLASH trials. Sleep. 2018;41(1):23. doi: 10.1093/sleep/zsx190.
Tandon VR, Sharma S, Mahajan A, et al.Menopause and sleep disorders. J Midlife Health. 2022;13(1):26–33. doi: 10.4103/jmh.jmh_18_22.
Maki PM, Jaff NG., Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570–578. doi: 10.1080/13697137.2022.2122792.
Davis SR, Baber RJ., Treating menopause–MHT and beyond. Nat Rev Endocrinol. 2022;18(8):490–502. doi: 10.1038/s41574-022-00685-4.
Harlow SD, Burnett-Bowie S-AM, Greendale GA, et al.Disparities in reproductive aging and midlife health between Black and White women: the Study of Women’s Health Across the Nation (SWAN). Womens Midlife Health. 2022;8(1):3. doi: 10.1186/s40695-022-00073-y.
Thurston RC, Joffe H., Vasomotor symptoms and menopause: findings from the Study of Women’s Health across the Nation. Obstet Gynecol Clin North Am. 2011;38(3):489–501. doi: 10.1016/j.ogc.2011.05.006.
Carson MY, Thurston RC., Vasomotor symptoms and their links to cardiovascular disease risk. Curr Opin Endocr Metab Res. 2023;30:24. doi: 10.1016/j.coemr.2023.100448.
Thurston RC, El Khoudary SR, Tepper PG, et al.Trajectories of vasomotor symptoms and carotid intima media thickness in the study of women’s health across the nation. Stroke. 2016;47(1):12–17. doi: 10.1161/STROKEAHA.115.010600.
Santoro N, Roeca C, Peters BA, et al.The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021;106(1):1–15. doi: 10.1210/clinem/dgaa764.
Johansson T, Karlsson T, Bliuc D, et al.Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024;387:e078784. doi: 10.1136/bmj-2023-078784.
Menegaz de Almeida A, Oliveira P, Lopes L, et al.Fezolinetant and Elinzanetant therapy for menopausal women experiencing vasomotor symptoms. Obstetrics & Gynecology. 2025. doi: 10.1097/AOG.0000000000005812.
Grandi G, Di Vinci P, Sgandurra A, et al.Contraception during perimenopause: practical guidance. Int J Womens Health. 2022;14:913–929. doi: 10.2147/IJWH.S288070.
Sourouni M, Kiesel L., Menopausal hormone therapy and the breast: a review of clinical studies. Breast Care. 2023;18(3):164–171. doi: 10.1159/000530205.
Villa P, Bounous VE, Amar ID, et al.Hormone replacement therapy in post-menopause hormone-dependent gynecological cancer patients: a narrative review. J Clin Med. 2024;13(5):1443. doi: 10.3390/jcm13051443.
Hickey M, Basu P, Sassarini J, et al.Managing menopause after cancer. Lancet. 2024;403(10430):984–996. doi: 10.1016/S0140-6736(23)02802-7.
Simon J., Are Low Dose Vaginal Oestrogens Safe for the Endometrium?Paper presented at: 19th World Congress on Menopause; 2024 Oct 19–22; Melbourne, Australia; 2024.
